european_commission_web

EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits

pharmafile | May 21, 2018 | News story | Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta 

The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the treatment of multiple sclerosis (MS), do not outweigh its risks, following a review carried out by the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) at the request of the European Commission.

The PRAC confirmed that the drug “poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs”, and that “patients could be at risk from the start of treatment and for several months after stopping treatment, and it is not possible to predict which patients will be affected”.

The investigation followed 12 reports linking Zinbryta to cases of inflammatory brain disorders around the world such as encephalitis and meningoencephalitis, with three cases resulting in death. On 6 March, the PRAC recommended that the product be pulled from the European market, and by 27 March, Biogen and Abbvie voluntarily withdrew the drug from all markets.

Despite the fact that the review confirmed the PRAC’s original recommendation, there will be no immediate impact of the findings as Zinbryta is not currently authorised in the EU. The drug was first awarded approval in the region in 2016 for the treatment of relapsing forms of MS in adults.

Matt Fellows

Related Content

EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …

louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …

AstraZeneca’s Voydeya recommended for approval in EU by CHMP

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European …

Latest content